Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Begrivac 2010/2011 in Adults and Elderly
NCT01147081Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Jul 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Agrippal S1 in seasonal influenza, sponsored by Novartis. Primary endpoints: Evaluation of antibody response to each influenza vaccine antigen at Day 22 and Evaluation of safety of Begrivac at Day 22. Started Jun 2010; status: completed.
02
Drugs
Agrippal S1
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT01147081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147081.